MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    A Parkinson’s disease (PD) case with underlying cerebral small vessel disease (CSVD)

    L.X Cao, W. Dong, Y. Li, G. Du, J.H Yin, Q. Yang, Y.Q Zhang, B. Chen, Y. Huang (Beijing, China)

    Objective: Emphasis of CSVD in PD through clinical-pathological correlation study. Background: PD affects 1.7%, while CSVD affects about 45% [1], of the population aged over…
  • MDS Virtual Congress 2020

    Parkinson’s disease and osteocalcin pilot study: Is there a protective role of bone in neurodegeneration?

    A.S Nordvig, R.N Alcalay, J.M Berger, K. Marder, G. Karsenty, A. Wang (New York, NY, USA)

    Objective: To characterize the relationship between the bone-derived hormone osteocalcin (OCN) and Parkinson’s disease (PD) in humans, and explore sex and treatment differences. Background: The…
  • MDS Virtual Congress 2020

    Neuroimaging of anxiety in Parkinson’s disease: a systematic review

    G. Carey, M. Görmezoğlu, K. Dujardin, A. Leentjens (Maastricht, Netherlands)

    Objective: The aim of this systematic review was 1) to identify the brain regions involved in anxiety in Parkinson's disease (PD) based on neuroimaging studies,…
  • MDS Virtual Congress 2020

    Clinical and neurological features of the course of parkinsonism in the presence of chronic renal disease

    S. Khudayarova, G. Rakhmatullaeva (Tashkent, Uzbekistan)

    Objective: To study the clinical and neurological features of the course of parkinsonism in chronic renal disease. Background: Under our supervision were 30 patients with…
  • MDS Virtual Congress 2020

    IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: A real-life study

    B. Bergmans, V. Schotte, N. Sys, E. Van Massenhove, M. Van Zandijcke (Brugge, Belgium)

    Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea (10 injection cycles into the…
  • MDS Virtual Congress 2020

    Assessing the Safety and Tolerability of ABBV-951 (Foscarbidopa/Foslevodopa) in Advanced Parkinson’s Disease Patients During a 52-Week Phase 3 Study: Study Design and Updated Patient Baseline Characteristics

    M. Facheris, J. Streit, J. Jia, D. Standaert (North Chicago, IL, USA)

    Objective: To evaluate the local and systemic safety and tolerability of ABBV-951 (foscarbidopa/foslevodopa) delivered 24 h/day as a continuous subcutaneous infusion (CSCI) for up to…
  • MDS Virtual Congress 2020

    Reduction of OFF time with apomorphine infusion during hours of pump use: Analysis from a Phase III, open-label study

    S. Isaacson, A. Espay, R. Pahwa, T. Clinch, P. LeWitt (Boca Raton, FL, USA)

    Objective: Evaluate the efficacy of apomorphine (APO) infusion in reducing OFF time during the hours of pump use in PD patients with motor fluctuations inadequately…
  • MDS Virtual Congress 2020

    Transcutaneous magnetic spinal cord stimulation for freezing of gait in Parkinson’s disease (PD)

    J.R Menezes, R.B Carra, G.A Nunes, J.S Simões, M.J Teixeira, K.P Duarte, D.C Andrade, E.R Barbosa, M.A Marcolin, R.G Cury (São Paulo, Brazil)

    Objective: To study the safety and efficacy of transcutaneous magnetic spinal cord stimulation (SCS) on freezing of gait (FoG) and other motor symptoms in a…
  • MDS Virtual Congress 2020

    Oral Venglustat in Parkinson’s Disease Patients With a GBA Mutation: Study Design of Part 2 of the MOVES-PD Trial and Patient Characteristics

    M.J Peterschmitt, T. Gurevich, T. Gasser, H. Saiki, S. Isaacson, C. Waters, A.M Wills, S. Hassin-Baer, T. Simuni, N. Hattori, S. Gaemers, S.P Sardi, S. Saubadu, P. Minini, T. Fischer (Cambridge, MA, USA)

    Objective: Describe the study design of Part 2 of the MOVES-PD trial (NCT02906020), and report patient characteristics. Background: Mutations in the glucocerebrosidase (GBA) gene are…
  • MDS Virtual Congress 2020

    Daily Time-Course of Efficacy of Continuous Subcutaneous Infusion of Foslevodopa/foscarbidopa in Advanced Parkinson’s Disease Patients from a Phase 1b Study

    S. Stodtmann, M. Rosebraugh, W. Robieson, M. Facheris (North Chicago, IL, USA)

    Objective: Characterize and compare the time-course of Parkinson’s disease (PD) symptoms following 24h/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa and oral levodopa/carbidopa (LD/CD). Background: As…
  • « Previous Page
  • 1
  • …
  • 146
  • 147
  • 148
  • 149
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley